Biological Efficacy of Interferon ß Therapy in Patients with Multiple
Monitoring of MxA mRNA Expression as a Marker of Rresponse to Interferon ß Therapy in Patients with Multiple Sclerosis.
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Interferon beta-1a
Interferon alpha/beta receptor agonist
- Interferon beta-1b
Interferon alpha/beta receptor agonist
- Rebif 22®
- Rebif 44®
What it measured
Main measures
The principal objective of our study is a prospective assesment of clinical efficacy of INFβ treatement correlated to MxA.
Immune response
Other measures (1)
The correlation of the titer of neutralizing antibodies(NAbs) and MxA.
Immune response
Who could take part
MS (type not specified)
Show the full criteria
Inclusion criteria
Inclusion: Male and female 18-55 years old Exclusion: Age less than 18 or more than 55.
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The principal objective of our study is a prospective assesment of clinical efficacy of INFβ treatement correlated to MxA.
Loading reviews and guidelines…
Related trials
- An Observational Study to Learn About the Interferon-beta Exposure of
Running, not recruiting
Still running
- US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage a
Completed
No results found
- PROmyBETAappGame: a Study to Learn More About the Medication Usage & P
Completed
No results found
- EPID Multiple Sclerosis Pregnancy Study
Completed
No results found
- Comparison Study of PF530 and Betaferon in Healthy Subjects
Phase 1 · Completed
No results found
- Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterfer
Phase 1 · Completed
Paper found, not read
History
Started
May 2011